Journal article

Neurocognitive outcomes in neurofibromatosis clinical trials Recommendations for the domain of attention

Karin S Walsh, Jennifer Janusz, Pamela L Wolters, Staci Martin, Bonita P Klein-Tasman, Mary Anne Toledo-Tamula, Heather L Thompson, Jonathan M Payne, Kristina K Hardy, Peter de Blank, Claire Semerjian, Laura Schaffner Gray, Sondra E Solomon, Nicole Ullrich

Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2016


Neurofibromatosis type 1 (NF1) is associated with neurocognitive deficits that can impact everyday functioning of children, adolescents, and adults with this disease. However, there is little agreement regarding measures to use as cognitive endpoints in clinical trials. This article describes the work of the Neurocognitive Committee of the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration. The goal of this committee is to identify standardized and specific cognitive assessment tools for use in NF clinical trials. The committee first identified cognitive domains relevant to NF1 and prioritized attention as the first domain of focus given prior an..

View full abstract